How should we measure the impact of chronic pain? Limitations of utility measurement using the EQ-5D and SF-6D

Affiliations

Comment

Deborah J Schofield. Pain. 2014 Oct.

. 2014 Oct;155(10):1918-1919.

doi: 10.1016/j.pain.2014.07.020. Epub 2014 Jul 30.

¹ NHMRC Clinical Trials Centre and School of Public Health, University of Sydney, 92-94 Parramatta Road, Camperdown, NSW 1450, Australia.

No abstract available

Comment on

Estimating the burden of disease in chronic pain with and without neuropathic characteristics: does the choice between the EQ-5D and SF-6D matter?
Torrance N, Lawson KD, Afolabi E, Bennett MI, Serpell MG, Dunn KM, Smith BH. Torrance N, et al. Pain. 2014 Oct;155(10):1996-2004. doi: 10.1016/j.pain.2014.07.001. Epub 2014 Jul 11. Pain. 2014. PMID: 25020004 Free PMC article.

1. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271-292.
1. Brazier J, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42:851-859.
1. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13:873-884.
1. Krahn M, Ritvo P, Irvine J, Tomlinson G, Bremner K, Bezjak A, Trachtenberg J, Naglie G. Patient and community preferences for outcomes in prostate cancer: implications for clinical policy. Med Care. 2003;41:153-164.
1. Postulart D, Adang E. Response shift and adaptation in chronically iii patients. Med Decis Making. 2000;20:186-193.